Antiplatelet and Antithrombotic Effect of Leaves and Mume Fructus Combination
Overview
Authors
Affiliations
Background: Agents currently used for the treatment and prevention of thrombosis have a number of side effects. We conducted this study to develop antithrombotic agents from herbs that are used in food.
Methods: The 80% (v/v) ethanol extracts of leaf (PL) and Mume Fructus (MF) and their combinations-2:1 (PM21), 1:1 (PM11), and 1:2 (PM12)-were evaluated on rat platelet aggregation induced by adenosine diphosphate (ADP) and on arteriovenous shunt thrombosis after 3 days of oral treatment in rats .
Results: At 100 μg/mL, PM21 and PM11 inhibited ADP-induced aggregation by 44.0 ± 4.3% and 30.0 ± 3.2%, respectively, whereas PL, MF, and PM12 weakly or scarcely inhibited ADP-induced aggregation by 3.9 ± 3.2%, 13.0 ± 2.7%, and 5.2 ± 1.3%, respectively. The IC values of PM21 on ADP-, collagen-, and thrombin-induced platelet aggregations were 135.6 ± 7.4 μg/mL, 142.7 ± 5.8 μg/mL, and 186.5 ± 9.7 μg/mL, respectively. In an rat arteriovenous-shunt thrombosis model, thrombus weight was significantly decreased after the oral administration of 400 mg/kg PL (27.8 ± 3.0%, < 0.01) or MF (35.2 ± 2.1%, < 0.01), and with a good accord to the results, the combination of PL and MF in the ratio of 2:1, PM21 (60.9 ± 1.2%, < 0.001), showed a superior antithrombotic effect to those of individual extracts. At dosages of 200 mg/kg, 100 mg/kg, and 50 mg/kg, PM21 dose-dependently decreased thrombosis weight (ED, 314 mg/kg).
Conclusion: These results suggest that combination preparations of PL and MF, especially their 2:1 combination, can increase antiplatelet and antithromboticeffects more than PL and MF alone, offering evidence for a potential novel combination antithrombotic therapy.
Gong X, Tang Y, Song Y, Du G, Li J Front Pharmacol. 2021; 12:679378.
PMID: 34122104 PMC: 8195681. DOI: 10.3389/fphar.2021.679378.
Kim E, Lee J, Lee H J Ginseng Res. 2021; 45(2):236-245.
PMID: 33841004 PMC: 8020352. DOI: 10.1016/j.jgr.2020.04.001.
Amirou A, Bnouham M, Legssyer A, Ziyyat A, Aziz M, Berrabah M Evid Based Complement Alternat Med. 2018; 2018:7313517.
PMID: 30186357 PMC: 6112207. DOI: 10.1155/2018/7313517.
Son E, Kim S, Yang W, Kim D, Cha J BMC Complement Altern Med. 2017; 17(1):541.
PMID: 29258493 PMC: 5738189. DOI: 10.1186/s12906-017-2032-5.